Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine

In 2019, the United States Food and Drug Administration accorded restricted approval to Sanofi Pasteur's Dengvaxia, a live attenuated vaccine (LAV) for dengue fever, a mosquito-borne viral disease, caused by four antigenically distinct dengue virus serotypes (DENV 1-4). The reason for this limi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Cell Infect Microbiol
Main Authors: Shukla, Rahul, Ramasamy, Viswanathan, Shanmugam, Rajgokul K., Ahuja, Richa, Khanna, Navin
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Cellular and Infection Microbiology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7642463/
https://ncbi.nlm.nih.gov/pubmed/33194810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcimb.2020.572681
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados